About
Kleanthis G. Xanthopoulos, Ph.D. is the President & Chief Executive Officer of Regulus Therapeutics Inc. joining Regulus around its formation in 2007. Prior to that, he was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals from its inception in 2000 to 2006, and remained a Director until its acquitision by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki,
Position in the VCSift Database
- • 2 investors at Shoreline Biosciences are tracked.
- • 2,540 investors hold the Co-Founder role in VCSift. Kleanthis G. Xanthopoulos is one of them.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Diego, US
Contact Information
Find more investors like Kleanthis
Search Investors